EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort

Roberta Gagliardini, Sara De Benedittis, Alessandro Tavelli iD, Giuseppe Lapadula, Valentina Mazzotta, Elena Bruzzesi, Adriana Cervo iD, Giorgia Carrozzo, Annalisa Saracino, Stefano Rusconi iD, Giulia Marchetti, Francesca Ceccherini-Silberstein und 4 weitere

Journal of Antimicrobial Chemotherapy · 01.08.2025 · 80 (8) · 2169-2178

DOI: 10.1093/jac/dkaf184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 17.06.2025. Verfasst von Roberta Gagliardini und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Rilpivirine, Pyridones. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Icona Foundation, Gilead Sciences, ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phase 3 studies have shown long-acting (LA) cabotegravir/rilpivirine to be effective and tolerable as maintenance therapy in people with HIV (PWH). However, real-life data on their effectiveness are limited.

Methods

All PWH enrolled in the Icona Cohort who started LA cabotegravir/rilpivirine with HIV-RNA < 50 copies/mL were included. Times to treatment discontinuation (TD) and to virological failure (VF50, two consecutive HIV-RNA >50 copies/mL or one >1000 copies/mL followed by ART switch) were estimated by the Kaplan–Meier method. Cox regression models, adjusted for age, sex and mode of HIV transmission and stratified by the centre, were employed.

Results

Overall, 583 PWH started LA cabotegravir/rilpivirine. Six VF50 were observed, with a 1 year estimated cumulative probability of virological failure of 1.2% (95% CI, 0.5%–3.0%). Resistance-associated mutations for rilpivirine and cabotegravir were detected in 3/4 and 4/4 participants with VF50, respectively, for which the genotypic resistance test was performed. The 1 year cumulative probability of TD was 11.4% (95% CI, 8.6%–14.9%), mainly caused by toxicity/adverse events (73.2%). Multivariable analysis identified heterosexual intercourse and IV drug use as significant risk factors for TD compared with MSM.

Conclusions

This analysis demonstrated the short-term effectiveness of cabotegravir/rilpivirine in a real-life setting showing minimal incidence of virological failure but a notable probability of discontinuation due to toxicity or adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsRilpivirinePyridonesWithholding TreatmentHumansMaleFemaleAdultMiddle AgedViral LoadCohort StudiesTreatment OutcomeDrug Resistance, ViralHIV-1RNA, ViralDiketopiperazines

Substanzen

Anti-HIV AgentsRilpivirinecabotegravirPyridonesRNA, ViralDiketopiperazines

Autor:innen und Institutionen

  • Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • ICONA Foundation, Milan, Italy.
  • National PhD Programme in One Health Approaches to Infectious Diseases and Life Science Research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.
  • IRCCS Fondazione San Gerardo dei Tintori, University of Milano Bicocca, Monza, Italy.
  • Infectious Diseses Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Infectious Diseases Clinic, University Hospital of Modena, Modena, Italy.

ORCID-Profile: Alessandro Tavelli, Adriana Cervo, Stefano Rusconi, Andrea Antinori, Camilla Muccini

Förderung

  • Icona Foundation
  • Gilead Sciences
  • ViiV Healthcare
  • Merck Sharpe & Dohme
  • Ricerca Corrente of the Italian Ministry of Health
  • Linea 2-progetto 2
  • INMI L. Spallanzani IRCCS

Zitieren

APA

Gagliardini, R., De Benedittis, S., Tavelli, A., Lapadula, G., Mazzotta, V., Bruzzesi, E., Cervo, A., Carrozzo, G., Saracino, A., Rusconi, S., Marchetti, G., Ceccherini-Silberstein, F., Antinori, A., d'Arminio Monforte, A., Muccini, C., & Icona Foundation Study Group (2025). Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort. Journal of Antimicrobial Chemotherapy, 80(8), 2169-2178. https://doi.org/10.1093/jac/dkaf184

Vancouver

Gagliardini R, De Benedittis S, Tavelli A, Lapadula G, Mazzotta V, Bruzzesi E, et al. Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort. Journal of Antimicrobial Chemotherapy. 2025;80(8):2169-2178. doi:10.1093/jac/dkaf184

BibTeX
@article{Gagliardini2025,
  author = {Gagliardini, Roberta and De Benedittis, Sara and Tavelli, Alessandro and Lapadula, Giuseppe and Mazzotta, Valentina and Bruzzesi, Elena and Cervo, Adriana and Carrozzo, Giorgia and Saracino, Annalisa and Rusconi, Stefano and Marchetti, Giulia and Ceccherini-Silberstein, Francesca and Antinori, Andrea and d'Arminio Monforte, Antonella and Muccini, Camilla and Icona Foundation Study Group, Icona Foundation Study Group},
  title = {Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {8},
  pages = {2169--2178},
  doi = {10.1093/jac/dkaf184}
}
Kostenlos starten →